BioStrand
Advancing technology for analyzing genetic data, which will drive innovation in the fields of precision medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €20.0m Valuation: €20.0m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
BioStrand, a Belgian bioinformatics company established in 2019 by Dr. Ingrid Brands and Dr. Arnout Van Hyfte, was acquired by ImmunoPrecise Antibodies (IPA) in May 2022. The founders' combined expertise in biotechnology and computational biology drove the creation of the company. Dr. Brands possesses a Ph.D. in biotechnology and an extensive background in R&D and business development within the life sciences sector, while Dr. Van Hyfte holds a Ph.D. in biotechnology, biochemistry, and structural biology, with deep experience in bioinformatics and data analysis.
The firm operates at the confluence of biotechnology and artificial intelligence, providing sophisticated analysis of biological data for therapeutic and diagnostic research. BioStrand targets pharmaceutical companies, biotech firms, and academic research institutions involved in drug discovery and development. Its business model centers on providing access to its powerful LENSai platform and proprietary HYFT technology, generating revenue through licensing, collaborative research projects, and providing specialized data analysis services.
At the core of BioStrand's offering is the LENSai Integrated Intelligence Platform, which is built upon its patented HYFT (HYperdimensional Feature-rich Text) technology. This technology harmonizes and analyzes massive, disparate omics data sets—including genomics, proteomics, and literature—by identifying unique structural patterns, or HYFTs, across them. The LENSai platform allows researchers to navigate this interconnected data landscape, revealing novel biological connections and accelerating the identification of drug targets, the discovery of biomarkers, and the overall process of therapeutic development. This unified approach to data integration and analysis allows for the de-risking of drug development pipelines and the uncovering of previously hidden insights.
Keywords: bioinformatics, drug discovery, omics data analysis, HYFT technology, LENSai platform, computational biology, therapeutic research, ImmunoPrecise Antibodies, data integration, structural biology